The Magnitude of TCR Engagement is a Critical Predictor of T Cell Anergy or Activation

Journal of Immunology

Volumn 172, Issue 9, 2004, Pages 5346-5355

  Mirshahidi, Saied ^a   Korb Ferris, Laura C ^a   Sadegh Nasseri, Scheherazade ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR1 ANTIGEN; PEPTIDE; PEPTIDE MAJOR HISTOCOMPATIBILITY ANTIGEN COMPLEX; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ACTIN POLYMERIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; CLONAL ANERGY; COMPLEX FORMATION; CONTROLLED STUDY; DISSOCIATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY CELL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE ACTIVATION;

EID: 2142771839     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.9.5346     Document Type: Article

References (53)

1. De Magistris, M. T., J. Alexander, M. Coggeshall, A. Altman, F. C. Gaeta, H. M. Grey, and A. Sette. 1992. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68:625.
2. Sloan-Lancaster, J., B. D. Evavold, and P. M. Allen. 1993. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363:156.
3. Madrenas, J., R. L. Wange, J. L. Wang, N. Isakov, L. E. Samelson, and R. N. Germain. 1995. ζ Phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science 267:515.
4. Lyons, D. S., S. A. Lieberman, J. Hampl, J. J. Boniface, Y. Chien, L. J. Berg, and M. M. Davis. 1996. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 5:53.
5. Kersh, G. J., E. N. Kersh, D. H. Fremont, and P. M. Allen. 1998. High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Immunity 9:817.
6. Germain, R. N., and I. Stefanova. 1999. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu. Rev. Immunol. 17:467.
7. Korb, L. C., S. Mirshahidi, K. Ramyar, A. A. Sadighi Akha, and S. Sadegh-Nasseri. 1999. Induction of T cell anergy by low numbers of agonist ligands. J. Immunol. 162:6401.
8. + T cells induced by low avidity engagement of T cell receptor. J. Exp. Med. 194:719.
9. Sadegh-Nasseri, S., and H. M. Mcconnell. 1989. A kinetic intermediate in the reaction of an antigenic peptide and 1-Ek. Nature 337:274.
10. Sadegh-Nasseri, S., and R. N. Germain. 1991. A role for peptide in determining MHC class II structure. Nature 353:167.
11. Sadegh-Nasseri, S., L. J. Stern, D. C. Wiley, and R. N. Germain. 1994. MHC class II function preserved by low-affinity peptide interactions preceding stable binding. Nature 370:647.
12. Sadegh-Nasseri, S., and R. N. Germain. 1992. How MHC class II molecules work: peptide-dependent completion of protein folding. Immunol. Today 13:43.
13. Sadegh-Nasseri, S. 1994. Peptide, invariant chain, or molecular aggregation preserves class II from functional inactivation. In Antigen Processing and Presentation. H. Pierce, ed. Academic. San Diego. p. 171.
14. Natarajan, S. K., M. Assadi, and S. Sadegh-Nasseri. 1999. Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. J. Immunol. 162:4030.
15. Rabinowitz, J. D., M. Vrljic, P. M. Kasson, M. N. Liang, R. Busch, J. J. Boniface, M. M. Davis, and H. M. Mcconnell. 1998. Formation of a highly peptide-receptive state of class II MHC. Immunity 9:699.
16. Kersh, G. J., M. J. Miley, C. A. Nelson, A. Grakoui, S. Horvath, D. L. Donermeyer, J. Kappler, P. M. Allen, and D. H. Fremont. 2001. Structural and functional consequences of altering a peptide MHC anchor residue. J. Immunol. 166:3345.
17. Wedderburn, L. R., S. J. Searle, A. R. Rees, J. R. Lamb, and M. J. Owen. 1995. Mapping T cell recognition: the identification of a T cell receptor residue critical to the specific interaction with an influenza hemagglutinin peptide. Eur. J. Immunol. 25:1654.
18. Rosloniec, E. F., D. D. Brand, L. K. Myers, K. B. Whittington, M. Gumanovskaya, D. M. Zaller, A. Woods, D. M. Altmann, J. M. Stuart, and A. H. Kang. 1997. An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J. Exp. Med. 185:1113.
19. Natarajan, S. K., L. J. Stern, and S. Sadegh-Nasseri. 1999. Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1. J. Immunol. 162:3463.
20. Chou, C.-L., and S. Sadegh-Nasseri. 2000. HLA-DM recognizes the flexible conformation of major histocompatibility complex class II. J. Exp. Med. 192:1697.
21. Sato, A. K., J. A. Zarutskie, M. M. Rushe, A. Lomakin, S. K. Natarajan, S. Sadegh-Nasseri, G. B. Benedek, and L. J. Stern. 2000. Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1. J. Biol. Chem. 275:2165.
22. Valitutti, S., S. Muller, M. Cella, E. Padovan, and A. Lanzavecchia. 1995. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148.
23. Samelson, L. E., and R. D. Klausner. 1992. Tyrosine kinases and tyrosine-based activation motifs: current research on activation via the T cell antigen receptor. J. Biol. Chem. 267:24913.
24. Denny, M. F., H. C. Kaufman, A. C. Chan, and D. B. Straus. 1999. The lck SH3 domain is required for activation of the mitogen-activated protein kinase pathway but not the initiation of T-cell antigen receptor signaling. J. Biol. Chem. 274:5146.
25. 2+ mobilization and Erk activation in Jurkat T cells in response to T-cell antigen receptor ligation. Mol. Cell. Biol. 21:7137.
26. Ota, Y., and L. E. Samelson. 1997. The product of the proto-oncogene c-cbl: a negative regulator of the Syk tyrosine kinase. Science 276:418.
27. 292 mediates the negative regulatory effect of Cbl on ZAP-70 in T cells. J. Immunol. 164:4616.
28. Sosinowski, T., A. Pandey, V. M. Dixit, and A. Weiss. 2000. Src-like adaptor protein (SLAP) is a negative regulator of T cell receptor signaling. J. Exp. Med. 191:463.
29. + thymocytes and regulates positive selection. Immunity 15:457.
30. Huang, J., D. Tilly, A. Altman, K. Sugie, and H. M. Grey. 2000. T-cell receptor antagonists induce Vav phosphorylation by selective activation of Fyn kinase. Proc. Natl. Acad. Sci. USA 97:10923.
31. Villalba, M., K. Bi, F. Rodriguez, Y. Tanaka, S. Schoenberger, and A. Altman. 2001. Vav1/Rac-dependent actin cytoskeleton reorganization is required for lipid raft clustering in T cells. J. Cell Biol. 155:331.
32. Miranti, C. K., L. Leng, P. Maschberger, J. S. Brugge, and S. J. Shattil. 1998. Identification of a novel integrin signaling pathway involving the kinase Syk and the guanine nucleotide exchange factor Vav1. Curr. Biol. 8:1289.
33. Villalba, M., J. Hernandez, M. Deckert, Y. Tanaka, and A. Altman. 2000. Vav modulation of the Ras/MEK/ERK signaling pathway plays a role in NFAT activation and CD69 up-regulation. Eur. J. Immunol. 30:1587.
34. Monks, C. R., B. A. Freiberg, H. Kupfer, N. Sciaky, and A. Kupfer. 1998. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395:82.
35. Grakoui, A., S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and M. L. Dustin. 1999. The immunological synapse: a molecular machine controlling T cell activation. Science 285:221.
36. Penninger, J. M., and G. R. Crabtree. 1999. The actin cytoskeleton and lymphocyte activation. Cell 96:9.
37. Wulfing, C., A. Bauch, G. R. Crabtree, and M. M. Davis. 2000. The Vav exchange factor is an essential regulator in actin-dependent receptor translocation to the lymphocyte-antigen-presenting cell interface. Proc. Natl. Acad. Sci. USA 97:10150.
38. Rosette, C., G. Werlen, M. A. Daniels, P. O. Holman, S. M. Alam, P. J. Travers, N. R. Gascoigne, E. Palmer, and S. C. Jameson. 2001. The impact of duration versus extent of TCR occupancy on T cell activation: a revision of the kinetic proofreading model. Immunity 15:59.
39. Baker, B. M., S. J. Gagnon, W. E. Biddison, and D. C. Wiley. 2000. Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: implications for TCR signaling. Immunity 13:475.
40. Ding, Y. H., B. M. Baker, D. N. Garboczi, W. E. Biddison, and D. C. Wiley. 1999. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 11:45.
41. Rudolph, M. G., J. G. Luz, and I. A. Wilson. 2002. Structural and thermodynamic correlates of T cell signaling. Annu. Rev. Biophys. Biomol. Struct. 31:121.
42. Beeson, C., and H. M. Mcconnell. 1994. Kinetic intermediates in the reactions between peptides and proteins of major histocompatibility complex class II. Proc. Natl. Acad. Sci. USA 91:8842.
43. b upon peptide binding. Biochemistry 37:3001.
44. Stern, L. J., J. H. Brown, T. S. Jardetzky, J. C. Gorga, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215.
45. Jardetzky, T. S., J. C. Gorga, R. Busch, J. Rothbard, J. L. Strominger, and D. C. Wiley. 1990. Peptide binding to HLA-DRI: a peptide with most residues substituted to alanine retains MHC binding. EMBO J. 9:1797.
46. Holsinger, L. J., I. A. Graef, W. Swat, T. Chi, D. M. Bautista, L. Davidson, R. S. Lewis, F. W. Alt, and G. R. Crabtree. 1998. Defects in actin-cap formation in Vav-deficient mice implicate an actin requirement for lymphocyte signal transduction. Curr. Biol. 8:563.
47. Sims, T. N., and M. L. Dustin. 2002. The immunological synapse: integrins take the stage. Immunol. Rev. 186:100.
48. + T cells. Science 271:1276.
49. Clements, J. L., N. J. Boerth, J. R. Lee, and G. A. Koretzky. 1999. Integration of T cell receptor-dependent signaling pathways by adapter proteins. Annu. Rev. Immunol. 17:89.
50. Macian, F., F. Garcia-Cozar, S. H. Im, H. F. Horton, M. C. Byrne, and A. Rao. 2002. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109:719.
51. Penninger, J. M., K. D. Fischer, T. Sasaki, I. Kozieradzki, J. Le, K. Tedford, K. Bachmaier, P. S. Ohashi, and M. F. Bachmann. 1999. The oncogene product Vav is a crucial regulator of primary cytotoxic T cell responses but has no apparent role in CD28-mediated co-stimulation. Eur. J. Immunol. 29:1709.
52. Bielekova, B., B. Goodwin, N. Richert, I. Cortese, T. Kondo, G. Afshar, B. Gran, J. Eaton, J. Antel, J. A. Frank, et al. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6:1167.
53. Kappos, L., G. Comi, H. Panitch, J. Oger, J. Antel, P. Conlon, and L. Steinman. 2000. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial: the altered peptide ligand in relapsing MS study group. Nat. Med. 6:1176.